OVV compared with TAK: revenue, margins and what each company keeps, and the suppliers and customers both name

OVVOvintiv Inc.

Mkt capRevenueRevenue

TAKTakeda Pharmaceutical Co Ltd

Mkt capRevenueRevenue

Compare

OVVOvintiv Inc.

TAKTakeda Pharmaceutical Co Ltd

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

OVV

Reportimpliedrealized× implied

Q2 FY26—▲+2.83%—

May 12 '26—▼−1.69%—

Q1 FY26—▼−1.46%—

Nov 5 '25—▼−1.74%—

TAK1 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Oct 29 '26±12.8%▼−0.69%×0.05

= impliedOVV realized, solidTAK realized, hatchedOne scale, both sides: full bar = 13%× = |realized| ÷ impliedSource: market data

OVVOvintiv Inc.

72.61· pre 72.62· delayed

Mkt cap$20.0BRevenue$3.0BQ2 FY26Revenue$8.9BFY25

TAKTakeda Pharmaceutical Co Ltd

20.92· pre 20.93· delayed

Pre-marketOct 30 '26delayed

Mkt cap$36.0BRevenue—Revenue—

Compare

Pre-marketOct 30 '26delayed

OVVOvintiv Inc.

TAKTakeda Pharmaceutical Co Ltd

72.61pre 72.62delayed

Price

20.92pre 20.93delayed

$20.0B

Mkt cap

$36.0B

Q2 FY26$3.0B

Revenue

—

FY25$8.9B

Revenue

—

OVV72.61vsTAK20.92Pre-marketOct 30 '26delayed